SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings (SPHL) is experiencing intense investor interest driven by a newly announced strategic partnership for solar and green-energy solutions in Singapore. The community is actively discussing the stock's extremely low float, fueling speculation about significant short squeeze potential and prompting expectations of highly volatile price action. While many anticipate a substantial upward move, a segment of traders urges caution, referencing the ticker's history of sharp price fluctuations.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial (RILY) is trending after filing its Q3 financial results, showcasing renewed profitability and NASDAQ compliance. This development has ignited intense community discussion around a potential short and gamma squeeze, with many comparing it to past explosive market events due to high short interest and a constrained float.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending after securing approval for an additional 830 megawatts at its Helios Data Center Campus, doubling its total power capacity to over 1.6 Gigawatts. The community is hailing this as a game-changing development, significantly re-rating GLXY's valuation as a key hybrid player in both the institutional crypto market and the burgeoning AI infrastructure sector.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

CNSP is trending due to its recent Orphan Drug designation for TPI-287, a treatment for brain cancer, sparking excitement around potential upside. The community is actively discussing the stock's low float and potential for a squeeze, with some analysts targeting significantly higher prices. Despite a history of reverse stock splits, the focus remains on the potential of CNSP's glioblastoma pipeline.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is trending strongly after delivering an impressive earnings report that surpassed expectations, fueled by robust demand for advanced AI chips. The semiconductor giant's optimistic guidance and substantial capital expenditure plans are widely viewed by the community as a powerful affirmation of the accelerating AI infrastructure build-out. This performance is boosting sentiment across the broader semiconductor sector and reinforcing confidence in the long-term AI megatrend.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is actively discussed amidst political negotiations concerning the extension of Affordable Care Act (ACA) subsidies, with a recent House vote favoring a multi-year extension driving investor attention. The community is sharply divided; optimists foresee a potential short squeeze and significant upside if a bipartisan agreement is reached in the Senate, while others caution about declines if a favorable outcome doesn't materialize. This ongoing debate, coupled with recent analyst attention, places OSCR at the forefront of healthcare sector conversations.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical ($DRTS) is trending amidst high anticipation for imminent Japanese regulatory approval and a key presentation at a major healthcare conference this week, further bolstered by recent compelling pancreatic cancer data. The community is actively discussing the stock's pioneering Alpha DaRT technology and its life-saving potential in difficult-to-treat cancers, believing it remains significantly undervalued as it garners increasing institutional interest and ETF attention.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae is actively trending amid discussions surrounding a significant directive for it and Freddie Mac to purchase mortgage bonds, a move largely viewed by the community as a strategic step towards recapitalization and eventual release from conservatorship. This development, coupled with reported bullish sentiment from prominent investors, is fueling widespread anticipation for an impending IPO or uplisting, intended to boost housing affordability by lowering mortgage rates. However, some investors remain cautious, citing past delays and uncertainty regarding the precise timeline for these long-awaited changes.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

AI summary generating... hang tight! 🤖 Beep boop bop...

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 956.9% during the 3rd quarter, according to the company in its most recent disclosure...

SG Americas Securities LLC Buys 13,369 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

SG Americas Securities LLC increased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 216.2% in the third quarter, according to the company in its most recent filing with the...

<ul class="summary-bullets"><li>Imcivree is Rhythm’s only approved drug and the company is now looking forward to an FDA approval for the drug in the treatment of acquired hypothalamic obesity.</li><li>The FDA is expected to rule on the company’s application by March 20, 2026.</li><li>The company is also exploring the drug’s potential in treating other rare diseases including congenital hypothalamic obesity and Prader-Willi Syndrome.</li></ul>Shares of Rhythm Pharmaceuticals, Inc. (RYTM) jumped 4% on Friday after the company reported preliminary full-year Imcivree revenue of approximately $194 million, marking a growth of about 50% from FY24.Fourth quarter Imcivree revenue is expected to be about $57 million, marking a quarter-on-quarter growth of 11%. Imcivree is Rhythm’s only approved drug and the company is now looking forward to an approval from the U.S. Food and Drug Administration (FDA) for the drug in the treatment of <a href="https://stocktwits.com/news-articles/markets/equity/rhythm-pharma-experimental-drug-yields-weight-reduction-in-brain-damage-related-obesity/chFy2A1R5KT">acquired hypothalamic obesity.</a>The FDA is expected to rule on the company’s application by March 20, 2026.<h2 class="st-heading-2">Imcivree’s Current Use</h2>Imcivree is currently approved by the FDA to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients two years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome. Bardet-Biedl syndrome is a rare genetic disorder affecting multiple body systems, characterized by vision loss, obesity, kidney problems, genital abnormalities, and learning disabilities.About 70% of the drug’s revenue for the year and the fourth quarter came from U.S. sales, Rhythm said. The company is also exploring the drug’s potential in treating other rare diseases including congenital hypothalamic obesity and <a href="https://stocktwits.com/news-articles/markets/equity/rhythm-pharmaceuticals-stock-rises-after-positive-study-data-for-setmelanotide-in-treating-genetic-disorder/cLIxj7cREFG">Prader-Willi Syndrome</a> in addition to advancing its other experimental drugs Bivamelagon and RM-718 in acquired hypothalamic obesity.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RYTM stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that the preliminary revenue numbers put speculation of slowing revenue growth to rest.<stembedurl>https://www.stocktwits.com/Stonky_Mcprofitface/message/641320511</stembedurl><a href="https://stocktwits.com/symbol/RYTM">RYTM stock</a> has gained 80% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-incurs-7.1-billion-in-charges-in-q4/cmUbl4LR451">General Motors Incurs $7.1B In Charges In Q4 Pertaining To Slowing EV Demand, China Business Restructuring</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March

Fourth quarter Imcivree revenue is expected to be about $57 million, marking a quarter-on-quarter growth of 11%.

Equity

Fourth quarter Imcivree revenue is expected to be about $57 million, marking a quarter-on-quarter growth of 11%.


Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 3.3% - Should You Sell?

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 3.3% - Should You Sell...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has received an average recommendation of "Moderate Buy" from the nineteen brokerages that are presently covering the stock, MarketBeat...

Harbor Capital Advisors Inc. Has $3.76 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

Harbor Capital Advisors Inc. trimmed its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 57.0% in the third quarter, according to the company in its most recent filing...

Equities Analysts Offer Predictions for RYTM FY2025 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings per share estimates for Rhythm Pharmaceuticals in a report issued on Monday...

Voya Investment Management LLC Has $22.38 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM

Voya Investment Management LLC lessened its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 9.2% during the third quarter, according to its most recent filing with the...

Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Assenagon Asset Management S.A. cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $167.00 at Citizens Jmp

Citizens Jmp lifted their target price on Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the company a "market outperform" rating in a research report on Friday...

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.82	--	--	N/A
Q3 '25	-$0.71	-$0.82	-15.80%	MISSED
Q2 '25	-$0.67	-$0.75	-11.92%	MISSED
Q1 '25	-$0.69	-$0.81	-16.68%	MISSED
Q4 '24	-$0.65	-$0.72	-10.41%	MISSED

RYTM
Rhythm Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RYTM News

RYTMRhythm Pharmaceuticals Inc.